Professor Michel Krempf
Nantes (France)
Pharmacokinetics and pharmacodynamics of alirocumab in patients with autosomal dominant hypercholesterolemia associated with PCSK9 gain-of-function or ApoB loss-of-function mutations
Event: ESC Congress 2018
Topic: Lipid-Lowering Agents
Session: Innovative drug therapies
What is atherogenic dyslipidaemia? Does it really exist?
Event: ESC CONGRESS 2014
Topic: Epidemiology, lipids
Session: Combination therapy in dyslipidaemia. What is new in Europe?
ESC 365 is supported by
